{"id":44855,"date":"2014-08-21T16:11:44","date_gmt":"2014-08-21T20:11:44","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=44855"},"modified":"2014-08-21T16:11:44","modified_gmt":"2014-08-21T20:11:44","slug":"fda-grants-apixaban-expanded-indication-venous-thromboembolism","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2014\/08\/21\/fda-grants-apixaban-expanded-indication-venous-thromboembolism\/","title":{"rendered":"FDA Grants Apixaban Expanded Indication for Venous Thromboembolism"},"content":{"rendered":"<p>The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis,\u00a0Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) after initial therapy.\u00a0The supplemental new drug application was based on findings from the previously published\u00a0<a title=\"New Anticoagulant Found Safe and Effective in Acute Venous Thromboembolism\" href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/new-anticoagulant-found-safe-and-effective-in-acute-venous-thromboembolism\/\">AMPLIFY<\/a>\u00a0and\u00a0<a title=\"Prolonged Anticoagulation with Apixaban Beneficial in Venous Thromboembolism\" href=\"http:\/\/blogs.nejm.org\/cardioexchange\/news\/prolonged-anticoagulation-with-apixaban-beneficial-in-venous-thromboembolism\/\">AMPLIFY-EXT<\/a>\u00a0studies.<\/p>\n<p>All three of the new oral anticoagulants \u2014 dabigatran (Pradaxa, Boehringer Ingelheim), rivaroxaban (Xarelto), and apixaban \u2013\u00a0have now gained both the VTE indication as well as the indication for stroke prevention\u00a0in patients with nonvalvular atrial fibrillation (SPAF). Rivaroxaban and apixaban are also approved for\u00a0DVT prophylaxis following hip- or knee-replacement surgery.<\/p>\n<p>Both\u00a0apixaban and rivaroxaban were studied using a single-drug approach for acute use in the hospital and for continued use afterwards. By contrast, dabigatran was studied in patients after they had received parenteral anticoagulants and is indicated for use following treatment with a parenteral anticoagulant for 5 to 10 days.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA today approved an expanded indication for the oral anticoagulant apixaban (Eliquis,\u00a0Bristol-Myers Squibb and Pfizer). Apixaban will now be indicated for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE (collectively known as venous thromboembolism) after initial therapy.\u00a0The supplemental new [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[495,1],"tags":[367,196,2343,1154,1191,748],"class_list":["post-44855","post","type-post","status-publish","format-standard","hentry","category-anticoagulation-2","category-general","tag-dvt","tag-fda","tag-noacs","tag-oral-anticoagulants","tag-pe","tag-vte"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/44855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=44855"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/44855\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=44855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=44855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=44855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}